SCHEMBL23628801

SCHEMBL23628801

N#Cc1ccc(N2CC(CN3CCC4(CCCNC4)CC3)C3(CC3)C2)c2nccnc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 8/20 0.43
CYP1A2 P05177 4/20 0.43
CYP2D6 P10635 6/20 0.38
ALDH1A1 P00352 5/20 0.38
MAPK1 P28482 1/20 0.38
TSHR P16473 2/20 0.37
HSD17B10 Q99714 2/20 0.36
HPGD P15428 1/20 0.36
RET P07949 5/20 0.35
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
ROCK1 Q13464 3/20 0.34
CDC42BPB Q9Y5S2 3/20 0.34
ROCK2 O75116 2/20 0.34
CDC42BPA Q5VT25 2/20 0.34
TLR9 Q9NR96 2/20 0.34
TLR8 Q9NR97 2/20 0.34
TLR7 Q9NYK1 2/20 0.34
SYK P43405 1/20 0.33
USP2 O75604 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23628736 0.97 CYP3A4 (0.45) CYP3A4CYP1A2CYP2D6ALDH1A1MAPK1
SCHEMBL23628770 0.94 CYP3A4 (0.38) CYP3A4CYP1A2CYP2D6ALDH1A1MAPK1
SCHEMBL23628807 0.89 USP2 (0.38) CYP3A4CYP1A2CYP2D6ALDH1A1MAPK1
SCHEMBL23760676 0.89 TLR8 (0.36) CYP3A4CYP1A2CYP2D6ROCK1CDC42BPB
SCHEMBL23628837 0.88 USP2 (0.36) CYP3A4CYP1A2CYP2D6ALDH1A1TSHR
SCHEMBL23628874 0.87 TLR9 (0.37) ROCK1CDC42BPBROCK2CDC42BPATLR9
SCHEMBL23628756 0.85 SLC6A2 (0.43) TLR9TLR8TLR7SYK
SCHEMBL23628729 0.83 CDC42BPB (0.44) RETROCK1CDC42BPBROCK2CDC42BPA
SCHEMBL23628808 0.83 TLR8 (0.39) RETROCK1CDC42BPBROCK2TLR9
SCHEMBL23628873 0.82 TLR9 (0.41) RETROCK1CDC42BPBROCK2TLR9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210253575-A1 PYRROLIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE HOFFMANN-LA ROCHE INC. (US) 2021-08-19 US claimed
EP-3847165-A1 NOVEL PYRROLIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2021-07-14 EP claimed
US-20210253575-A1 PYRROLIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE HOFFMANN-LA ROCHE INC. (US) 2021-08-19 US disclosed
US-20210253575-A1 PYRROLIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE HOFFMANN-LA ROCHE INC. (US) 2021-08-19 US disclosed
EP-3847165-A1 NOVEL PYRROLIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2021-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210253575-A1 PYRROLIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE ARG1, PRMT1, PADI1 CYP3A4 3575/4885CYP1A2 2291/4885CYP2D6 2859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.